Multiple Myeloma

>

Latest News

Additionally, the Chinese Society of Clinical Oncology and Chinese Anti-Cancer Association guidelines recommend the isatuximab regimen for this population.
Isatuximab Combo Earns Chinese Approval in R/R Multiple Myeloma

January 16th 2025

Additionally, the Chinese Society of Clinical Oncology and Chinese Anti-Cancer Association guidelines recommend the isatuximab regimen for this population.

Subcutaneous Isatuximab Shows Noninferior ORR, C Trough in R/R Myeloma
Subcutaneous Isatuximab Shows Noninferior ORR, C Trough in R/R Myeloma

January 9th 2025

Anito-cel produced no delayed or non–immune effector cell–associated neurotoxicity syndrome among patients with multiple myeloma.
Data Show Enduring Efficacy with Anito-cel in R/R Multiple Myeloma

December 30th 2024

CAR T-Cell Therapy Is a Desirable Option in Second-Line Multiple Myeloma
CAR T-Cell Therapy Is a Desirable Option in Second-Line Multiple Myeloma

December 30th 2024

Experts Discuss Choosing Bispecifics and Sequencing Options in Multiple Myeloma
Experts Discuss Choosing Bispecifics and Sequencing Options in Multiple Myeloma

December 27th 2024